Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Laryngeal Neoplasms 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Temozolomide 53Bevacizumab 33Radiotherapy 27Radiation 12Erlotinib Hydrochloride 12Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Irinotecan 6Vorinostat 5Sorafenib 5Sirolimus 5temsirolimus 4Magnetic Resonance Spectroscopy 4Immunoglobulin G 4Disulfides 4Carmustine 4veliparib 3plerixafor 3carmustine, poliferprosan 20 drug combination 3Radiosurgery 3Everolimus 3Dasatinib 3Bortezomib 3vandetanib 2tandutinib 2sargramostim 2poly ICLC 2pembrolizumab 2pazopanib 2ferric pyrophosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gliosarcoma × gossypol acetic acid × Clear all
NCT00540722 2017-08-11

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡